Japanese intractable and rare dermatologic diseases: From the official skin-centered nanbyo core to an illustrative...

Japan's designated intractable disease (nanbyo) framework combines a population threshold with unresolved pathogenesis or treatment, long-term care needs, objective diagnostic criteria, and severity-linked assistance with medical expenses. We conducted a targeted narrative review of official Japanese sources and biomedical literature through August 3, 2026. Evidence ranged from regulatory approvals and randomized trials to observational, case-report, and preclinical data, so therapeutic maturity was assessed separately from mechanistic plausibility. We distinguished the 12 official skin/connective-tissue entries from six purposively selected designated entries or disease groups with decisive cutaneous phenotypes or Japan-specific translational value. The resulting 18-entry framework is illustrative, not exhaustive. It highlights Japan-specific biology or evidence regarding xeroderma pigmentosum, acquired idiopathic generalized anhidrosis, DPP-4 inhibitor-related bullous pemphigoid, generalized pustular psoriasis, cold-medicine-related SJS/TEN, anti-MDA5 dermatomyositis, and Nakajo-Nishimura syndrome. Recently approved indications or uses include dupilumab for adult bullous pemphigoid, IL-36 receptor blockade, topical COL7A1 gene delivery, autologous gene-corrected epidermal sheets, MEK inhibition, IL-1 blockade, and topical mTOR inhibition; JAK-interferon strategies remain investigational. We contend that Japan's designation infrastructure could become an interoperable translational platform linking natural-history cohorts, endotype-defined enrollment, mechanism-aligned endpoints, and multinational adaptive trials.